SOUTH SAN FRANCISCO, Calif.,
Jan. 3, 2022 /PRNewswire/
-- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic
lethality focused precision medicine oncology company committed to
the discovery and development of targeted therapeutics, announced
its participation in investor conferences in January 2022.
LifeSci Advisors Corporate Access Event
Thursday, Jan 6, 2022 at 4:00pm ET
- Panel presentation "Precision Oncology – Delivering the Right
Treatment to the Right Patients at the Right Time" with IDEAYA
participation by Yujiro Hata, Chief
Executive Officer, moderated by Robert
Humkey, Ph.D. and Matthew
Cook - Managing Partners, LifeSci Consulting
J.P. Morgan 40th Annual Healthcare Conference
Tuesday, January 11, 2022 at
9:45 am ET
- Presentation by Yujiro Hata,
Chief Executive Officer followed by analyst-hosted Q&A with
Anupam Rama, Managing Director, US
SMID Biotechnology Equity Research, J.P. Morgan
B. Riley Securities' 2022 Oncology Conference
Thursday, January 27, 2022
3:30pm ET
- Fireside chat with Yujiro Hata,
Chief Executive Officer, hosted by Mayank
Mamtani, Managing Director, Senior Biotech Research Analyst
Group, Head of Healthcare Research, B. Riley Securities
A live audio webcast of the event will be available, as
permitted by conference host, at the "Investors/News and
Events/Investor Calendar" section of the IDEAYA website at
https://ir.ideayabio.com/events. A replay of available
webcasts will be accessible for 30 days following the live
event.
About IDEAYA Biosciences
IDEAYA is a synthetic lethality-focused precision medicine
oncology company committed to the discovery and development of
targeted therapeutics for patient populations selected using
molecular diagnostics. IDEAYA's approach integrates
capabilities in identifying and validating translational biomarkers
with drug discovery to select patient populations most likely to
benefit from its targeted therapies. IDEAYA is applying its
early research and drug discovery capabilities to synthetic
lethality – which represents an emerging class of precision
medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to participation
in and/or presentation at certain investor relations events. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's
Quarterly Report on Form 10-Q filed on November 15, 2021 and any current and periodic
reports filed with the U.S. Securities and Exchange Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-investor-conferences-in-january-2022-301452415.html
SOURCE IDEAYA Biosciences, Inc.